ProShares Ultra NASDAQ Biotechnology
29 hedge funds and large institutions have $42.3M invested in ProShares Ultra NASDAQ Biotechnology in 2014 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 3 closing their positions.
400% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 3
200% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 3
88% more capital invested
Capital invested by funds: $22.6M → $42.3M (+$19.8M)
71% more funds holding
Funds holding: 17 → 29 (+12)
56% less call options, than puts
Call options by funds: $5.97M | Put options by funds: $13.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AP
Advisors Preferred
Rockville,
Maryland
|
+$7.11M |
| 2 |
Jane Street
New York
|
+$4.72M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$807K |
| 4 |
Morgan Stanley
New York
|
+$789K |
| 5 |
ACP
Aviance Capital Partners
Naples,
Florida
|
+$638K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ABI
Adamant Biomedical Investments
Zurich,
Switzerland
|
-$4.11M |
| 2 |
VCAM
Valentine Capital Asset Management
Danville,
California
|
-$1.49M |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
-$740K |
| 4 |
FTUS
Flow Traders U.S.
New York
|
-$662K |
| 5 |
BCM
Blume Capital Management
Berkeley,
California
|
-$31K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| $13K | -$11.7K | -200 | -50% |
|
|
SSG
27
Summit Securities Group
New York
| $13K | +$11.7K | +200 | New |
|
|
TCM
28
Tradewinds Capital Management
Bellingham,
Washington
| $1K | +$1.17K | +20 | New |
|
|
29
Verition Fund Management
Greenwich,
Connecticut
| – | -$740K | -14,228 | Closed |
|
|
FTUS
30
Flow Traders U.S.
New York
| – | -$662K | -12,730 | Closed |
|
|
BCM
31
Blume Capital Management
Berkeley,
California
| – | -$31K | -600 | Closed |
|
32
Parallax Volatility Advisers
San Francisco,
California
| – | +$117 | +2 | New |
|
BIB Hedge Fund Activity: Q4 2014 in Review
29 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q4 2014, worth a combined $42.3M — up 88% from $22.6M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new BIB positions and 3 closed out — a net gain of 12 holders — while 9 added to existing stakes and 3 trimmed.
The largest buyer was Advisors Preferred, opening a new position worth an estimated $7.11M. The largest seller was Adamant Biomedical Investments, cutting an estimated $4.11M.
- 29 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q4 2014, up from 17 in Q3 2014.
- Funds reported $42.3M of ProShares Ultra NASDAQ Biotechnology stock for Q4 2014, up 88% quarter-over-quarter.
- 15 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q4 2014 and 3 closed out, a net change of +12 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q4 2014 was Advisors Preferred, an estimated $7.11M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q4 2014 was Adamant Biomedical Investments, an estimated $4.11M sold.
Based on aggregated 13F filings for Q4 2014.